Spyre Therapeutics, Inc. (SYRE) has 12 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 7 sales totalling $410.6M. Most recent filing: Sept. 3, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 3, 2026 filed Sept. 1, 2026 | Burrows Scott L Chief Financial Officer | −$1,618,165 | 40,732 | −19% | Yes | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 1, 2026 | King-Jones Heidy See Remarks | — | 0 | 0% | Yes | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 1, 2026 | Turtle Cameron Chief Executive Officer | −$1,309,410 | 15,000 | −3% | Yes | |
|
|
||||||
| Aug. 10, 2026 filed Aug. 7, 2026 | Albers Jeffrey W. Director | −$1,881,540 | 33,000 | −29% | Yes | |
|
|
||||||
| Aug. 5, 2026 filed Aug. 3, 2026 | Burrows Scott L Chief Financial Officer | $608,021 | 22,500 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 12 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free